
VANDERBILT VIVERSITY

MEDICAL CENTER

Evaluating Patient-Reported Adherence and Outcomes in Specialty Disease States: A Dual Site Initiative

Chelsea P. Renfro¹, E. Danielle Bryan¹, Rebekah H. Anguiano², Lisa Kumor³, Lauren Moy³, Josh DeClercq⁴, Leena Choi⁴, Autumn D. Zuckerman¹

¹Specialty Pharmacy, Vanderbilt University Medical Center; ²National Association of Specialty Pharmacy; ³University of Illinois Chicago; ⁴Department of Biostatistics, Vanderbilt University Medical Center



Abbreviations: HCRU = healthcare resource utilization; HSSP = health system specialty pharmacy; PRO = patient-reported outcomes; MS = multiple sclerosis; ER = emergency room



College of Pharmacy



Setting and Patient Sample

Dual-center, retrospective review of monthly assessments completed by University of Illinois Hospital and Health Sciences System (UI Health) Specialty Pharmacy and Vanderbilt Specialty Pharmacy (VSP)

Patients were included if they were prescribed specialty medications from rheumatology or MS clinics and received at least three fills from October 2019 – March 2022, excluding patients with >30-day supply at any individual medication refill

Table 1. Patient Demographics


Site 2 (n=331) n (%)	Overall (n=3,677) n (%)
50 (40-61)	50 (37-61)
264 (80)	2,638 (72)
61 (18)	2,780 (76)
167 (51)	471 (13)
249 (75)	2,795 (76)
82 (25)	880 (24)
0 (0)	2 (<1)
	(n=331) n (%) 50 (40-61) 264 (80) 61 (18) 167 (51) 249 (75) 82 (25)


Patients filling rheumatology or MS specialty medications within HSSPs reported high rates of medication effectiveness and low rates of missed doses, issues with tolerability, and HCRU.

Patients reporting tolerability issues or lower perceived effectiveness were more likely to report a missed dose.

Table 2. Patient Medications **Assessed by Clinic**

Medication	Overall, n (%)	
Rheumatology Clinics (n=45,420)		
Adalimumab	16,643 (37)	
Etanercept	11,060 (24)	
Tofacitinib	4,408 (10)	
Multiple Sclerosis Clinics (n=16,506)		
Dimethyl fumarate	3,373 (20)	
Fingolimod	3,065 (19)	
Glatiramer acetate	3,021 (18)	





Conclusion